Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine + acetazolamide versus placebo in obesity hypoventilation syndrome
2022-000693-26Phase 2Completed
- Sponsor
- Istituto Auxologico Italiano
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of atomoxetine and acetazolamide in obesity hypoventilation syndrome (OHS) (2 arms), sponsored by Istituto Auxologico Italiano. Primary endpoint: Mean nocturnal transcutaneous carbon dioxide level. Started Feb 2022; status: completed.
02
Drugs
atomoxetineacetazolamide
03
Conditions
obesity hypoventilation syndrome (OHS)
Beyond the preview
Go deeper on 2022-000693-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000693-26.